[ad_1]
10x Genomics, Inc. (NASDAQ:TXG – Get Score) shares traded down 7.2% on Friday after an insider bought shares within the firm. The corporate traded as little as $35.84 and final traded at $35.90. 23,762 shares traded fingers throughout mid-day buying and selling, a decline of 98% from the typical session quantity of 1,253,785 shares. The inventory had beforehand closed at $38.68.Particularly, insider Benjamin J. Hindson bought 1,292 shares of 10x Genomics inventory in a transaction on Tuesday, August 23rd. The inventory was bought at a mean worth of $35.19, for a complete transaction of $45,465.48. Following the completion of the sale, the insider now straight owns 186,246 shares within the firm, valued at $6,553,996.74. The transaction was disclosed in a submitting with the SEC, which may be accessed by way of the SEC web site. In associated information, CFO Justin J. Mcanear bought 987 shares of 10x Genomics inventory in a transaction dated Tuesday, August 23rd. The inventory was bought at a mean worth of $35.19, for a complete worth of $34,732.53. Following the completion of the sale, the chief monetary officer now straight owns 58,092 shares within the firm, valued at $2,044,257.48. The transaction was disclosed in a submitting with the Securities & Trade Fee, which is accessible by way of this hyperlink. Additionally, insider Benjamin J. Hindson bought 1,292 shares of 10x Genomics inventory in a transaction dated Tuesday, August 23rd. The shares had been bought at a mean worth of $35.19, for a complete worth of $45,465.48. Following the completion of the sale, the insider now owns 186,246 shares of the corporate’s inventory, valued at $6,553,996.74. The disclosure for this sale may be discovered right here. During the last ninety days, insiders bought 4,994 shares of firm inventory value $175,739. 11.08% of the inventory is at present owned by insiders.
Analysts Set New Worth Targets
TXG has been the topic of various latest analysis studies. Cowen boosted their goal worth on shares of 10x Genomics to $55.00 in a report on Monday, August 15th. Cowen boosted their goal worth on shares of 10x Genomics from $50.00 to $55.00 in a report on Tuesday, August ninth. Canaccord Genuity Group initiated protection on shares of 10x Genomics in a report on Monday, July 25th. They issued a “purchase” ranking for the corporate. Financial institution of America downgraded shares of 10x Genomics from a “impartial” ranking to an “underperform” ranking and set a $35.00 goal worth for the corporate. in a report on Friday, July 15th. Lastly, Canaccord Genuity Group initiated protection on shares of 10x Genomics in a report on Monday, July 25th. They issued a “purchase” ranking and a $55.00 goal worth for the corporate. Two funding analysts have rated the inventory with a promote ranking, two have assigned a maintain ranking and 5 have assigned a purchase ranking to the corporate’s inventory. In keeping with MarketBeat.com, 10x Genomics has a mean ranking of “Maintain” and a consensus goal worth of $49.25.
10x Genomics Inventory Down 7.7 %
The inventory has a 50-day shifting common of $42.57 and a 200 day shifting common of $55.59. The inventory has a market cap of $4.03 billion, a PE ratio of -28.48 and a beta of 1.66.
10x Genomics (NASDAQ:TXG – Get Score) final launched its quarterly earnings information on Monday, August eighth. The corporate reported ($0.57) EPS for the quarter, lacking the consensus estimate of ($0.40) by ($0.17). 10x Genomics had a damaging return on fairness of 17.77% and a damaging internet margin of 28.62%. The corporate had income of $114.61 million in the course of the quarter, in comparison with analysts’ expectations of $115.89 million. Throughout the identical quarter within the prior 12 months, the corporate posted ($0.10) EPS. The corporate’s income for the quarter was down 1.1% on a year-over-year foundation. On common, equities analysts anticipate that 10x Genomics, Inc. will put up -1.73 EPS for the present 12 months.
Institutional Inflows and Outflows
A number of giant traders have just lately made adjustments to their positions in TXG. SRS Funding Administration LLC raised its stake in shares of 10x Genomics by 1,214.3% in the course of the 2nd quarter. SRS Funding Administration LLC now owns 2,758,245 shares of the corporate’s inventory value $124,811,000 after shopping for an extra 2,548,380 shares in the course of the interval. FMR LLC raised its stake in shares of 10x Genomics by 50.2% in the course of the 2nd quarter. FMR LLC now owns 6,195,527 shares of the corporate’s inventory value $280,347,000 after shopping for an extra 2,070,318 shares in the course of the interval. D1 Capital Companions L.P. acquired a brand new place in shares of 10x Genomics in the course of the 4th quarter value roughly $239,081,000. Sands Capital Administration LLC raised its stake in 10x Genomics by 92.4% within the 1st quarter. Sands Capital Administration LLC now owns 3,201,394 shares of the corporate’s inventory valued at $243,530,000 after buying an extra 1,537,427 shares over the past quarter. Lastly, BlackRock Inc. raised its stake in 10x Genomics by 14.2% within the 1st quarter. BlackRock Inc. now owns 9,156,992 shares of the corporate’s inventory valued at $696,572,000 after buying an extra 1,138,358 shares over the past quarter. 76.25% of the inventory is owned by institutional traders and hedge funds.
10x Genomics Firm Profile
10x Genomics, Inc, a life science expertise firm, develops and sells devices, consumables, and software program for analyzing organic methods in North America, Europe, the Center East, Africa, China, and the Asia Pacific. The corporate offers chromium and chromium join devices, microfluidic chips, slides, reagents, and different consumables merchandise.
See Additionally
This immediate information alert was generated by narrative science expertise and monetary information from MarketBeat with the intention to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you take into account 10x Genomics, you may need to hear this.
MarketBeat retains monitor of Wall Avenue’s top-rated and finest performing analysis analysts and the shares they suggest to their purchasers every day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and 10x Genomics wasn’t on the listing.
Whereas 10x Genomics at present has a “Maintain” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.
[ad_2]
Supply hyperlink